Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
The reaffirmed outlook calls for approximately 38% revenue growth over 2025, with the company expecting its strongest fourth quarter.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million, up 19% from the same period in 2025.
Revenue for the nine months ended September 30, 2026 rose from $45.6 million and was 35% above 2024. Preliminary third-quarter revenue reached approximately $17.4 million, up 2% from $17.1 million in 2025 and 40% from $12.4 million in 2024. Each quarter of 2026 exceeded its previous corresponding-quarter revenue record. Cana Laboratories' production pipeline exceeded 32.7 million units; CosmoFarm recorded its highest distribution volumes, and proprietary brands expanded into new markets and channels.
The company reaffirmed expected 2026 revenue of over $90 million, approximately 38% above 2025, and expects its highest-ever fourth-quarter revenue. The preliminary figures are unaudited and remain subject to quarter-end closing procedures and review.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointPreliminary nine-month revenue of approximately $54.3 million rose 19% versus 2025 and 35% versus 2024.
- Moderate point. Forward-looking: it has not happened yet and may not happen.2026 revenue outlook of over $90 million reaffirmed, implying approximately 38% growth over 2025.
- Minor pointPreliminary Q3 revenue of approximately $17.4 million rose 2% versus 2025 and 40% versus 2024.
- Minor pointEach 2026 quarter exceeded its previous corresponding-quarter revenue record.
- Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter revenue expected by Cosmos Health to be its highest ever, supported by orders, distribution seasonality and U.S. sales.
3 minor points
- Minor pointCana Laboratories' production pipeline reached a record of more than 32.7 million units.
- Minor pointCosmoFarm distribution volumes reached a record across its expanding pharmacy network.
- Minor pointProprietary brands grew in established markets and entered new territories and channels globally.
Negative
- Minor pointPreliminary, unaudited revenue figures remain subject to completion of quarter-end closing procedures and review.
Details
Market Reaction – COSM
On Oct 7, the day this news came out, the latest delayed price for COSM is 2.57% below the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $0.31. Relative volume is above average at 1.7x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Nine-month revenue
- $54.3 million
- Nine months ended September 30, 2026; preliminary and unaudited
- Nine-month revenue growth
- 19%
- Year over year; preliminary revenue
- Q3 revenue
- $17.4 million
- Third quarter 2026; preliminary and unaudited
- Q3 revenue growth
- 2%
- Versus third quarter 2025, as presented in the article table
- 2026 revenue outlook
- Over $90 million
- Full-year expectation reaffirmed; outlook, not results
Previous Earnings Reports
-
Q1 2026 revenue set a record and rose year over year, while the reported net loss widened.
-
FY 2025 revenue reached a record, establishing the full-year baseline referenced in this update.
-
Q3 2025 revenue reached a record and rose year over year, providing the comparable quarter baseline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
unaudited financial
form 10-q regulatory
good manufacturing practices regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / October 7, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced preliminary revenue of approximately
Nine Months That Nearly Equal a Full Year
In nine months, Cosmos Health has generated approximately the same revenue it reported for the whole of 2024, when full-year revenue was
Record Revenue in Every Quarter of 2026
First, second and third-quarter revenue each exceeded the highest revenue the Company had previously reported for that quarter. The third quarter was achieved against the most demanding comparison of the three.
Third-quarter revenue of approximately
| REVENUE | 2024 | 2025 | 2026 (PRELIM.) | VS. 2025 | VS. 2024 |
| Third quarter | ~ | + | + | ||
| Nine months to September 30 | ~ | + | + | ||
| Full year | Over | + | + |
2026 third-quarter and nine-month figures are preliminary and unaudited. Full-year 2026 reflects the Company's outlook, not results. Percentages are calculated on rounded figures.
Growth Across the Company's Core Segments
The increase reflects growth across each of the Company's core segments. Contract manufacturing at Cana Laboratories reached a record production pipeline of more than 32.7 million units, and pharmaceutical distribution at CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies that continues to expand. The Company's proprietary brands - among others, Sky Premium Life, C-Scrub and C-Sept - grew in their established markets and entered new territories and channels globally, while sales momentum in the United States continued to build.
2026 Outlook Reaffirmed: Over
Cosmos Health reaffirms its previously announced expectation that revenue for full-year 2026 will surpass
Greg Siokas, CEO of Cosmos Health, stated: "In nine months we have delivered approximately what took us a full year in 2024. Revenue of approximately
"That growth is coming from every part of the business. Our contract manufacturing pipeline is at a record level, our distribution volumes are the highest we have recorded, and our proprietary brands are growing in their established markets while reaching new ones.
"The infrastructure we have built over the past several years is now supporting every part of the business, and we enter the final quarter with momentum. We are reaffirming our outlook to surpass
Preliminary Results
The revenue figures in this release are preliminary and unaudited, are based on information available to management as of the date of this release, and remain subject to the completion of the Company's quarter-end financial closing procedures and review. Actual results may differ from these preliminary estimates. The Company's complete third-quarter results will be reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2026.
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.